|
Dr. Bird's investment activities focus on the healthcare industry, including companies in the biotechnology and medical device areas. He is currently a board member at AkaRx (cancer and hematology therapeutics), Horizon Therapeutics (novel fixed dose drug combinations), NuGen Technologies (research reagents), Portola Pharmaceuticals (a spin-out of COR/Millennium focused on cardiovascular therapeutics), Restoration Robotics (aesthetic surgery devices), ROXRO PHARMA (pain therapeutics), Vivios (cancer therapeutics) and Xoft Microtube (cancer radiation devices). He also represents Sutter Hill's investments in Acceleron Pharmaceuticals (metabolic therapeutics) and BÂRRX Medical (gastrointestinal devices). He formerly served as a director at Threshold Pharmaceuticals and Idun Pharmaceuticals, which was acquired by Pfizer in 2005. Dr. Bird was previously Senior Vice President, Business Operations at Gilead Sciences, where he worked from 1988 to 1990 and then 1992 to 2000. He was primarily responsible for several alliances with major pharmaceutical companies and helped Gilead to acquire NeXstar in a $550 million transaction. His commercial responsibilities included direct sales in the U.S. and Europe which generated $150 million in annual product revenue. Dr. Bird received a degree in Biological Sciences from Stanford in 1982, a Ph.D. in Cancer Biology in 1988 and a M.D. in 1992 from Stanford Medical School. | 